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a b s t r a c t
We propose a novel bottom-up approach to the bounding of low-dose human cancer risks from chemical exposures that does not rely at all upon high-dose data for human or animal cancers. This approach can thus be used to provide an independent ''reality check'' on low-dose risk estimates derived with doseresponse models that are fit to high-dose cancer data. The approach (1) is consistent with the ''additivity to background'' concept, (2) yields central and upper-bound risk estimates that are linear at all doses, and (3) requires only information regarding background risk, background (endogenous) exposure, and the additional exogenous exposure of interest in order to be implemented. After describing the details of this bottom-up approach, we illustrate its application using formaldehyde as an example. Results indicate that recent top-down risk extrapolations from occupational cohort mortality data for workers exposed to formaldehyde are overly conservative by substantial margins.
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Background
In 1976, Kenny Crump, David Hoel, Charles Langley, and Richard Peto published a landmark paper (Crump et al., 1976) showing that a non-decreasing dose-response relationship for cancer risk will be linear at sufficiently low doses as long as there is a non-zero background exposure to which the specific chemical exposures of interest simply add. This is the well-known ''additivity to background'' concept: at zero additional exposure, we are already somewhere up on the dose-response curve as a result of our non-zero background exposure, so the slope of the dose-response relationship at zero additional exposure will necessarily be non-zero and positive. Even a threshold dose-response relationship will have a nonzero slope at zero additional exposure if there are some individuals in the population of interest whose thresholds lie below their nonzero background exposure.
Then, in 1977, Crump, Harry Guess, and K.L. Deal published another landmark paper (Crump et al., 1977) that outlined the statistical and mathematical procedures for estimating and bounding the low-dose slope of the multistage dose-response model using constrained maximum likelihood methods and tumor data collected in laboratory animal bioassays conducted at very high exposure levels. It was in this paper that the now infamous ''q 1 ⁄ '', the upper 95% confidence bound on the coefficient of the linear term (i.e., the low-dose slope) of the presumed dose-response relationship, was created, and this value has dominated carcinogenic risk assessment ever since.
The dominance of q 1 ⁄ in risk assessment has been a consequence of two factors. First, there is the tyranny of small numbers, i.e., the small numbers of animals that have been utilized in laboratory animal carcinogenicity studies, typically, only about 50 animals per sex per dose group. This number is so small that even if the observed tumor incidence in a treated group is zero (0/50), the exact binomial upper 95% confidence bound on the true response probability is 0.0582, so true risks up to this value cannot be confidently ruled out. It is also not possible to distinguish statistically at the p = 0.05 level between a response as high as 0.08 (4/ 50 tumor-bearing animals) in a treated group and a null response (0/50) in a control group using Fisher's exact test. If the goal of risk assessment is to bound the dose of a chemical that is associated with an upper bound incremental cancer risk of only one per million (10 À6 ), then one can conservatively ''guesstimate'' the required dose, using the low-dose linear hypothesis, as being about 100,000-fold lower than the highest dose that produces no significant increase, compared to controls, in the probability of developing cancer. This is common knowledge among biostatisticians, and a source of frustration and heartburn among many toxicologists; it is, nevertheless, an irrefutable ''fact of life''.
The second factor behind the dominance of q 1 ⁄ is that until recently, the background exposures that may be responsible, at least in part, for our background cancer risks have not been quantified (two notable exceptions are radiation and our background body burdens of dioxin-like compounds). Generally, little attention has been focused on quantifying background chemical exposures, and the exposures of interest have routinely been expressed as increments above whatever the background exposures might be. This is primarily due to the fact that human background exposures are complicated, uncontrolled, and usually unmeasured, while the animal studies that attempt to carefully control and minimize these background exposures have not routinely included measures of the corresponding internal (endogenous) doses that can arise via normal metabolism and other internal biochemical reactions.
Without knowing what background exposure is, expressed preferably as the concentration of a relevant exposure biomarker, e.g., DNA adducts, in the target tissue of interest, the only way to estimate the slope of the dose-response relationship at low doses has been via downward extrapolation from the observed tumor responses in small numbers of animals (or occupationally exposed people) at high external exposure levels, which forces us into the q 1 ⁄ conundrum. However, this situation has changed recently, and the change could profoundly alter carcinogenic risk assessment going forward, at least for those potentially carcinogenic substances that are always present in our bodies, even absent external exposure, because they are produced continuously by normal biochemical processes such as metabolism and biochemical synthesis and degradation. The key technological advance underpinning our novel ''bottom-up'' approach to risk assessment is the extraordinary ability to distinguish between and separately quantify the relevant internal exposures in target tissues that arise from internal background (endogenous) and external (exogenous) sources. In what follows, we outline this alternative approach to estimating and bounding low-dose cancer risks for such substances, and illustrate the potential for its application with the specific example of formaldehyde, an important commodity chemical that is currently under review by the US Environmental Protection Agency (USEPA).
The bottom-up approach
Let P 0 represent the background lifetime risk of a tissue-specific cancer in people, such as nasopharyngeal cancer or leukemia. Let C 0 represent the mean tissue-specific background steady-state concentration of a biomarker, such as a specific DNA adduct, that is presumed to be causally related to these cancers. Then the ratio P 0 /C 0 provides an estimate of the lowdose slope of the relationship between the cancer risk and the corresponding tissue-specific DNA adduct concentration. Similarly, if C 0L represents the lower 95% confidence bound estimate for the same background adduct concentration, then the ratio P 0 / C 0L provides an upper 95% confidence bound on the low-dose slope. This latter ratio is thus directly comparable to the q 1 ⁄ derived from high dose animal studies, as well as the upper bound slope estimates for the low-dose linear dose-response relationships that are typically inferred from epidemiologic analyses of occupational cohort cancer mortality, provided only that the dose metrics used in these two kinds of studies (animal bioassays and cohort mortality studies) are converted into the corresponding equivalent tissue-specific adduct concentrations.
The key elements of this bottom-up approach are illustrated in Fig. 1 . What is most important to appreciate is that the central and upper bound slope estimates derived using this approach do not depend in any way on high-dose carcinogenicity data for laboratory animals or humans. The approach thus provides a completely independent ''reality check'' on low-dose slope estimates like q 1 ⁄ that are derived from analyses of highdose laboratory animal tumor incidence data or occupational cancer mortality data.
An illustration of the bottom-up approach using currently available data for formaldehyde
Formaldehyde is a highly reactive chemical and an essential metabolic intermediate that is generated endogenously in all living cells, and N 2 -hydroxymethyl-deoxyguanosine (dG) adducts have been detected and quantified in various tissues of rats (Lu et al., 2010 and and cynomolgus macaques exposed to various concentrations of stable isotope-labelled [ 13 CD 2 ]-formaldehyde by inhalation. These formaldehyde-DNA adducts are potentially promutagenic because adduction takes place on the amino groups participating in Watson-Crick base pairing, and adduct formation is widely considered to be a key event in the initiation of mutations that lead to carcinogenesis . Thus, the tissue-specific concentration of these adducts provides an excellent internal dose metric with which to illustrate the bottom-up approach to bounding the low-dose slope of dose-response relationships for human cancer risk.
The use of [ 13 CD 2 ]-formaldehyde permits the simultaneous measurement of both endogenous and exogenous formaldehyde-DNA adducts with sensitive Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry-Selected Reaction Monitoring (LC-ESI-MS/MS-SRM) methods. While endogenous dG adducts were detected in all of the examined tissues, exogenous dG adducts formed with inhaled [ 13 CD 2 ]-formaldehyde were detected only in the tissues taken from the site of initial contact with exogenous formaldehyde, i.e., rat and monkey nasal respiratory epithelium .
Because no exogenous dG adducts were detected in these studies in any distant site tissues, including bone marrow and the blood, we can state with confidence that if such exogenous adducts were present in these tissues, then their amounts would necessarily have been smaller than the LC-ESI-MS/MS-SRM method's detection limit (DL). We have therefore used the method's DL (reported in Moeller et al. (2011) as 20 Â 10 À18 mol) as a worst case upper bound on the level of exogenous dG adducts that could be present and yet remain undetected in the bone marrow of [ 13 CD 2 ]-formaldehyde-exposed monkeys. The above molar DL was converted to an equivalent DL expressed in terms of the number of adducts, namely, 1.03 Â 10 À3 per 10 7 dG, using the average amount of monkey DNA collected in the bone marrow samples , and the amount of guanine (0.20, expressed as a fraction) that is present in monkey DNA (Casanova et al., 1991) . The formaldehyde-DNA adduct data utilized in our bottom-up slope calculations are provided in Table 1 . These values are the mean ± standard error of the number of endogenous and exogenous dG adducts per 10 7 dG in nasal respiratory epithelium (2.49 ± 0.23 and 0.25 ± 0.020, respectively), and the bone marrow (17.5 ± 1.31, endogenous dG adducts only) as determined in monkeys following two 6 h exposures to 2 ppm [ 13 CD 2 ]-formaldehyde (data taken from Table 3 in Swenberg et al., 2011) . Also presented are the lower 95% confidence bound estimates for endogenous dG adducts in both tissues, i.e., the mean values minus 1.645 times their respective standard errors.
We have also estimated the corresponding steady-state exogenous dG adduct levels that would result from continuous 24 h/day, 7 days/week exposure. To accomplish this, we used the adduct levels measured in monkeys by Moeller et al. (2011) immediately after the two 6 h exposures (30 h after the onset of the first exposure), together with a simple one compartment linear kinetic model of adduct buildup and elimination with a 63 h elimination half-life (mean adduct lifetime T = 63/ln(2) = 90.9 h) as has been determined in rats (Swenberg et al., 2012) . For example, if C x30 represents the measured exogenous DNA adduct concentration after two 6 h exposures on consecutive days to a given airborne formaldehyde concentration, and C xS-S represents the model-predicted asymptotic steady-state adduct concentration that would result from continuous exposure to the same airborne formaldehyde concentration, then
The steady-state adduct concentrations that are predicted by this formula to arise from continuous lifetime exposure to 2 ppm [ 13 CD 2 ]-formaldehyde are also provided in Table 1 .
At present, we do not have estimates of endogenous or exogenous dG adduct concentrations in human tissues, so we have made the simple assumption that the DNA adduct data collected by Moeller et al. (2011) in cynomolgus macaques are directly relevant to humans without any interspecies scaling adjustments. For the background lifetime risks of developing nasopharyngeal cancer (NPC) and leukemia (LEU), we have relied on two different sources. For NPC, we have taken the estimate of 7.25 Â 10 À4 that is provided in USEPA's 2 June 2010 draft formaldehyde assessment (see Table C -1, p C-3 and Section 5.2.2). For leukemia, we used the Both Sexes, All Race lifetime risk estimate of 1.3 Â 10 À2 from Table 1 .14 of SEER Cancer Statistics Review 1975 -2007 (Altekruse et al., 2010 . Table 2 presents the results from using the bottom-up approach with these data and assumptions to calculate upper bound estimates of human nasopharyngeal cancer and leukemia risk from lifetime continuous exposure to 1 ppm formaldehyde. To obtain bottom-up estimates corresponding to 1 ppm formaldehyde, we first calculated bottom-up estimates for 2 ppm (the lowest exposure level used by Moeller et al. (2011) , and then simply divided those estimates by a factor of two, since the bottom-up approach assumes linearity of the dose-response relationship. We chose 1 ppm so as to be able to compare our risk estimates simply and directly with those derived by USEPA from epidemiologic data using cumulative formaldehyde exposure as the dose metric, namely 0.011 ppm À1 for NPC and 0.057 ppm À1 for leukemia (see Table 6 -3, pp 6-41-6-42 of the Agency's draft assessment).
For nasopharyngeal cancer (NPC), the bottom-up upper bound risk estimate (0.038 Â 10 À2 ) is nearly 29-fold lower than USEPA's ''plausible upper bound'' estimate of 1.1 Â 10 À2 , i.e., about 1%. In contrast, the bottom-up upper bound estimate of leukemia risk (<3.9 Â 10 À6 ) is more than 14,000-fold lower than the corresponding USEPA estimate of 5.7 Â 10 À2 , i.e., about 6%. The marked disparity between these estimated cancer risks for this distant site suggests strongly that the excess risk of leukemia that has been reported in association with workplace formaldehyde exposures is not due to those exposures. If our plausible assumption that formaldehyde dG adducts provide a valid molecular dosimeter for relating potential human cancer risks to formaldehyde exposure is correct, then the much larger risks derived by USEPA from the adult human cancer data are overly conservative.
Strengths and limitations of the bottom-up approach
We are confident that the estimates obtained from this simple approach to bounding low-dose human cancer risks are conservative for several reasons. Most importantly, the bottom-up approach attributes all of the background risk of specific cancers to the endogenous formaldehyde dG adducts that are found in the corresponding tissues. If only a fraction f of the total background risk P 0 were due to the background endogenous adduct concentration C 0 , then it is only this fraction of the total background risk P 0 to which our assumed linear dose-response relationship should apply. The slope estimate P 0 /C 0 and the associated upper 95% confidence bound described herein would therefore exaggerate the actual slope of the low-dose response and its upper estimated 95% confidence bound by the factor 1/f. Table 1 Endogenous and exogenous DNA adduct concentrations (per 10 7 dG) in nasal epithelial tissue and bone marrow of cynomolgus macaques exposed via inhalation for 6 h on two consecutive days to 2 ppm [ 13 CD 2 ]-formaldehyde (data taken from Moeller et al. (2011) ). Also shown are the 8.85-fold higher steady-state exogenous adduct concentrations that are expected to result from lifetime continuous inhalation exposure to 2 ppm [ 13 CD 2 ]-formaldehyde (see text for details). Moeller et al. (2011) .
Table 2
Comparison of estimated lifetime risks of developing nasopharyngeal cancer (NPC) and leukemia (LEU) from continuous lifetime inhalation exposure to 1 ppm formaldehyde, as estimated with the bottom-up approach and, alternatively, by USEPA using top-down linear extrapolation from epidemiologic data (as taken from Table 6 -3, pp 6-41-6-42 of the Agency's 2 June 2010 draft assessment).
Cancer
Background risk, P 0 Bottom-up slope, P 0 /C 0L a Bottom-up risk at 1 ppm b USEPA risk at 1 ppm NPC 7.25 Â 10 À4 3.44 Â 10 À4 0.038 Â 10 À2 1.1 Â 10 À2 LEU 1.30 Â 10 À2 8.50 Â 10 À4 <3.9 Â 10 À6 5.7 Â 10 À2 a for NPC, 3.44 Â 10 À4 = 7.25 Â 10 À4 /2.11 for LEU, 8.50 Â 10 À4 = 1.30 Â 10 À2 /15.3. b for NPC, 0.038 Â 10 À2 = 3.44 Â 10 À4 Â (2.21/2) for LEU, <3.9 Â 10 À6 = 8.50 Â 10 À4 Â (<0.00912/2). Second, the approach is linear at low doses simply because it assumes linearity at all doses. This can create problems if we extrapolate the bounding bottom-up risk estimates to very high exogenous exposure levels, such as those producing statistically significant increases in tumor incidence in exposed laboratory animals or humans. At such levels, it is expected that the dose-response relationship for tumor incidence may well be highly nonlinear due to a variety of factors that become important only at high doses, such as cytotoxicity, tissue damage, and enhanced cell proliferation that markedly increases the probability of mutations. Such non-genotoxic high dose phenomena are not accounted for in our simple linear model, so the confidence bounds that it generates should not be expected to hold at the high exogenous exposures where these phenomena take place.
Third, we have used lower 95% confidence bounds on the estimated mean endogenous DNA adduct levels (C 0 ) to generate, by simple inversion, the corresponding upper 95% confidence bounds on the slope (P 0 /C 0 ) of the linear relationship that has been assumed between cancer risks and steady-state adduct concentrations. This follows directly from a Taylor series expansion of the ratio P 0 /C 0 about its expected value when P 0 is taken to be constant, as we have assumed herein, and only the estimated mean background DNA adduct concentration C 0 has uncertainty associated with it. In this special case, the variance of the ratio P 0 /C 0 is given approximately by (c.f., Stuart and Ord, 1994, p. 351) :
If uncertainty in the estimate of the mean background risk P 0 is also characterized and it is independent of, i.e., uncorrelated with, the uncertainty in C 0 , as is the case herein, because the estimates of P 0 and C 0 are derived from two completely different data sets, then the additional uncertainty in the estimated ratio P 0 /C 0 that is due to the uncertainty in P 0 can also be readily accommodated (ibid.):
The upper 95% confidence bound on the slope estimate P 0 /C 0 is thus increased as a result of incorporating the additional uncertainty in P 0 . Additional discussion of uncertainty in the estimate of the ratio P 0 /C 0 in a linear regression context is provided in the Appendix.
Fourth, for the case of leukemia, exogenous DNA adducts were never detected in monkey bone marrow even though the methodology has sufficient statistical power to detect a single N 2 -hydroxymethyl-deoxyguanosine adduct in 10 billion deoxyguanosine molecules. We have therefore assumed, as a worst case, that exogenous DNA adducts could have been present at a level just barely below the detection limit of the ultrasensitive LC-ESI-MS/MS-SRM methodology. One could reduce this estimate substantially using less conservative assumptions regarding the sampling distribution of non-detected exogenous DNA adduct concentrations (c.f., Ginevan and Splitstone, 2003, pp 123-125) .
Fifth, we have made reasonable assumptions in converting adduct concentrations measured in monkey tissues after two 6 h/day exposures to 2 ppm airborne formaldehyde on consecutive days to the higher steady-state adduct levels that would arise from continuous exposures to the same airborne formaldehyde concentration for a lifetime, but our extrapolation using a simple linear pharmacokinetic model has not yet been validated. Data from longer term studies out to 28 consecutive days of exposure are currently being analyzed, so the remaining uncertainty regarding the half-life of formaldehyde DNA adducts should be better resolved in due course.
Even so, the cross-species extrapolation from DNA adduct data obtained in monkeys to human formaldehyde exposures remains unvalidated. However, unvalidated assumptions can be replaced at some point with data-driven alternatives. For example, in the near future, we expect to obtain data regarding endogenous formaldehyde dG adducts in human tissues. Human blood samples are readily obtainable, and opportunistic sampling of other critical tissues such as nasal tissue and bone marrow is certainly possible. Such data could be used to confirm and/or replace our plausible dosimetric assumption that endogenous formaldehyde dG adduct amounts in monkey and human tissues are directly comparable. Obtaining exogenous adduct concentrations in humans may be more problematic. However, the extraordinary sensitivity of the Lu et al. (2010 Lu et al. ( , 2011 and Moeller et al. (2011) methodology may offer the prospect of detecting such adducts using short-term voluntary human exposures.
Finally, another important limitation of the bottom-up approach is its reliance on the assumption of a linear dose-response relationship between cancer risks and DNA adduct concentrations in target tissues, even though the true dose-response may be highly nonlinear at sufficiently high exogenous exposure levels. For this reason, we advocate the bottom-up approach only as a potential means for generating tighter upper bounds on low-dose human cancer risks than it may be possible to achieve with top-down approaches. The bottom-up approach may not be appropriate for developing ''best'' or central estimates of low-dose human cancer risks which, at least in our view, can best be accomplished through a comprehensive and deep mechanistic understanding of how chemical exposures give rise to human cancer.
Summary
The Lu et al. (2010 Lu et al. ( , 2011 and Moeller et al. (2011) LC-ESI-MS/ MS-SRM methodology differentiates clearly between DNA adducts formed with formaldehyde molecules of endogenous and exogenous (inhaled) origin. This remarkable technological achievement has made it possible to develop upper-bound estimates of potential cancer risk with a unique bottom-up approach that extrapolates upward from background (endogenous) exposures and background cancer risks, as opposed to the typical top-down extrapolations from cancer incidence in laboratory animals or human workers subjected to very high exposure levels.
While we have illustrated the bottom-up approach with the example of formaldehyde, we expect it to be readily generalizable to other chemicals. For example, vinyl chloride, ethylene oxide, methanol, and acetaldehyde are all known to produce specific DNA adducts from endogenous and exogenous sources, and other chemicals are likely to be added to this list in the near future. The target tissue dose concept can also be generalized to include other forms of endogenous DNA damage, such as abasic sites, lesions arising from oxidative stress, and also biomarkers of effect, such as mutations (Swenberg et al., 2008 . The potential of the bottom-up approach to impact human cancer risk assessment appears great.
We used the new molecular dosimetry information for formaldehyde DNA adducts in the bottom-up approach to estimate upper-bound lifetime human nasopharyngeal cancer and leukemia risks that might arise from continuous inhalation exposure to 1 ppm formaldehyde. This provides a totally independent ''reality check'' on estimates derived with the conventional top-down approach to human cancer risk assessment. Comparison of the resulting bottom-up risk estimates with corresponding top-down estimates derived by USEPA from epidemiologic data for exposed workers show the latter to be markedly higher. The large discrepancies between the results we obtained with molecular dosimetry data incorporated into the bottom-up approach and those that relied on worker cancer mortality and uncertain retrospective occupational exposure reconstructions call into serious question the credibility of attributing large increases in human mortality from these cancers to occupational formaldehyde exposure.
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